ストックスクリーナーアプリを入手
4.13
1.10%
0.045
アフターアワーズ：
4.06
-0.07
-1.69%
前日終値:
$4.085
開ける：
$4.15
24時間の取引高:
678.92K
Relative Volume:
1.17
時価総額：
$389.54M
収益：
$9.01M
当期純損益:
$-99.72M
株価収益率:
-0.9101
EPS:
-4.5381
ネットキャッシュフロー:
$-92.85M
1週間 パフォーマンス:
+3.51%
1か月 パフォーマンス:
+2.23%
6か月 パフォーマンス:
+6.17%
1年 パフォーマンス:
+108.59%
1日の値動き範囲:
$4.08
$4.305
1週間の範囲:
$3.98
$4.70
52週間の値動き範囲:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.13 | 440.47M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | 開始されました | Guggenheim | Buy |
| 2025-12-05 | 再開されました | Stifel | Buy |
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
Form 4 Shuttle Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
X4 Pharmaceuticals CFO David Kirske sells $36,428 in common stock By Investing.com - Investing.com Canada
Form 4 X4 Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
X4 Pharmaceuticals (XFOR) CFO sells 8,543 shares to cover RSU tax - Stock Titan
Director Kelly Gold granted 110,000 X4 Pharmaceuticals (XFOR) stock options at $4.085 - Stock Titan
X4 Pharmaceuticals (XFOR) director Gold Kelly files initial Form 3 ownership - Stock Titan
Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee - Stock Titan
X4 Pharmaceuticals Announces Appointment of Kelly Gold as an Independent Director and Member of the Audit Committee, Effective July 1, 2026 - marketscreener.com
Form 4 Adial Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue - The Manila Times
X4 Pharmaceuticals appoints Kelly Gold to board of directors By Investing.com - Investing.com Canada
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors - The Manila Times
X4 Pharmaceuticals adds CAMP4 CFO Kelly Gold to its board - Stock Titan
Form 4 Ionis Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Processa Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Eton Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Nigeria
Form 4 Vertex Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Tarsus Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com South Africa
Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com South Africa
Cadrenal Therapeutics (NASDAQ: CVKD) names interim CFO and realigns board classes - Stock Titan
Universe Pharmaceuticals (NASDAQ:UPC) pop puts $10.75M patent deal and float in focus - TechStock²
6,000 vTv Therapeutics (VTVT) options granted to director tied to Baker funds - Stock Titan
Tarsus Pharmaceuticals (TARS) director receives RSU and stock option grants - Stock Titan
Following Satri Cel Approval Is CARsgen Therapeutics Holdings (SEHK:2171) Fully Priced? - simplywall.st
Is Alnylam Pharmaceuticals (ALNY) Undervalued Following Its Expanded Komodo Health AI Partnership? - simplywall.st
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2000 Index - marketscreener.com
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? - TradingView
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today - TradingView
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2000 Value Benchmark - marketscreener.com
Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight - PR Newswire
Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Canada
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) added to Russell Microcap Value Benchmark Index - marketscreener.com
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom - Investing News Network
Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief - Stock Titan
BioCryst (NASDAQ: BCRX) lowers 2026 expenses and closes Birmingham R&D hub - Stock Titan
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - PR Newswire
5 Biotech Stocks That Skyrocketed 105% To 235% — TWST, INDV, MIRM & More - RTTNews
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell Microcap Index - marketscreener.com
Is Spyre Therapeutics (SYRE) Fully Valued After Russell Index Removal And A $500 Million Offering? - simplywall.st
Pfizer’s CFO Just Left and a Key Drug Trial Missed. Here’s What That Means for PFE Stock in 2026 - TIKR.com
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP - BioSpace
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2500 Index - marketscreener.com
BridgeBio's achondroplasia drug posts NEJM Phase 3 data - Stock Titan
XFOR Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 ARS Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan - Stock Titan
Form 4 Ionis Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
BVF group sells 1,630,658 Kymera (KYMR) shares in joint Form 4 - Stock Titan
Form 144 IONIS PHARMACEUTICALS INC For: 26 June By Investing.com - Investing.com Canada
ARS Pharmaceuticals (NASDAQ: SPRY) grants 30,000 options to RA Capital-linked director - Stock Titan
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
X 4 Pharmaceuticals Inc (XFOR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| KIRSKE DAVID | Chief Financial Officer |
May 12 '26 |
Sale |
4.29 |
16,961 |
72,820 |
176,293 |
3.86%
大文字化:
|
ボリューム (24 時間):